Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer by Chougule, Mahavir B. et al.
Antitumor Activity of Noscapine in Combination with
Doxorubicin in Triple Negative Breast Cancer
Mahavir B. Chougule
1, Apurva R. Patel
2, Tanise Jackson
2, Mandip Singh
2*
1College of Pharmacy, University of Hawaii, Hilo, Hawaii, United States of America, 2College of Pharmacy, Florida A&M University, Tallahassee, Florida, United States of
America
Abstract
Background: The aim of this study was to investigate the anticancer activity and mechanism of action of Noscapine alone
and in combination with Doxorubicin against triple negative breast cancer (TNBC).
Methods: TNBC cells were pretreated with Noscapine or Doxorubicin or combination and combination index values were
calculated using isobolographic method. Apoptosis was assessed by TUNEL staining. Female athymic Nu/nu mice were
xenografted with MDA-MB-231 cells and the efficacy of Noscapine, Doxorubicin and combination was determined. Protein
expression, immunohistochemical staining were evaluated in harvested tumor tissues.
Results: Noscapine inhibited growth of MDA-MB-231 and MDA-MB-468 cells with the IC50 values of 36.1663.76 and
42.764.3 mM respectively. The CI values (,0.59) were suggestive of strong synergistic interaction between Noscapine and
Doxorubicin and combination treatment showed significant increase in apoptotic cells. Noscapine showed dose dependent
reduction in the tumor volumes at a dose of 150–550 mg/kg/day compared to controls. Noscapine (300 mg/kg),
Doxorubicin (1.5 mg/kg) and combination treatment reduced tumor volume by 39.465.8, 34.265.7 and 82.964.5 percent
respectively and showed decreased expression of NF-KB pathway proteins, VEGF, cell survival, and increased expression of
apoptotic and growth inhibitory proteins compared to single-agent treatment and control groups.
Conclusions: Noscapine potentiated the anticancer activity of Doxorubicin in a synergistic manner against TNBC tumors via
inactivation of NF-KB and anti-angiogenic pathways while stimulating apoptosis. These findings suggest potential benefit
for use of oral Noscapine and Doxorubicin combination therapy for treatment of more aggressive TNBC.
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Introduction
Approximately 30–40% of breast cancers are estrogen receptor
(ER) negative and the triple negative breast cancer (TNBC i.e.
negative for ERa, PR and Her2 amplification) are the most
clinically aggressive breast tumors [1,2]. TNBC relapses quickly in
response to clinical treatment as this subtype of breast cancer has a
high histological grade and poor prognosis [3]. Patients with
TNBC, which account for about 10–17% of all breast cancer cases
[4], are often unresponsive to endocrine agents such as tamoxifen
and less responsive to standard adjuvant therapy [5]. Specific
targeted therapies are not available to improve clinical outcome
among TNBC patients. [4,5] TNBC do not respond to endocrine
agents or trastuzumab and can only be treated with chemotherapy
and treatment options for these tumors are limited by frequent de
novo or acquired resistance to chemotherapy [6]. The limited
availability of current systemic treatment options for TNBC
necessitates the search for newer chemotherapeutic regimens. A
promising target for the treatment of these ER
2 breast tumors is
the microtubule cytoskeleton [7]. The effectiveness of microtubule-
interfering agents, taxanes and vinca alkaloids in treatment of
various cancers has been well studied [8]. However, the clinical
utility of taxanes has been limited due to drug-resistance, need of
i.v. infusion over a long period of time and associated toxicities
[9,10]. This has prompted search for microtubule targeting agent
that may be administered orally, display favorable toxicity profiles
and have better therapeutic indices in the treatment of TNBC.
Noscapine attenuates microtubule dynamics just enough to
activate the mitotic checkpoints to stop cell cycle and does not
alter the steady state monomer/polymer ratio of tubulin [11,12].
Noscapine showed antitumor activity against a variety of cancer
types (melanoma [13], ovarian [14], lymphoma [15], human
myelogenous leukemia [16], gliobastoma [17], lung, [18] and
breast [19]) both in vitro and in vivo while exerting minimal
adverse side effects. Furthermore, Noscapine also showed little or
no toxicity to the kidney, heart, liver, bone marrow, spleen, or
small intestine and did not inhibit primary humoral immune
responses in mice. Previous studies demonstrated that oral
administration of Noscapine at 120 mg/kg and 300 mg/kg
showed significant reduction in tumor volume in MCF-7 [19]
and MDA-MB-231 [20] xenografts in nude mice. However, the
effectiveness of Noscapine in combination with other anticancer
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present, the lack of highly effective therapeutic targets for TNBC
leaves standard chemotherapy, for example use of combination of
anthracycline and taxane, however these agents are insufficiently
efficacious [21]. Doxorubicin is an anthracycline drug which is
used as a chemotherapeutic agent for patients with metastatic
breast cancer and has shown overall response rates between 35
and 50% in patients with TNBC who have not previously received
chemotherapy [22]. Despite its excellent anti-tumor activity,
Doxorubicin has a relatively low therapeutic index and its clinical
utility is limited due to acute and chronic toxicities such as
myelosuppression, immunosupression and dose-cumulative car-
diotoxicity [23]. Therefore, combination treatment with another
highly effective novel non-toxic drug which can lower the dose of
chemotherapeutic agents would be desirable.
Given the challenge in treating ER
2 breast tumors and its
inherent poor prognosis, the use of Noscapine in combination
Doxorubicin will have major clinical implications for the treatment
of ER
2 breast cancer. Based on the individual activity of these
agents and their distinct mechanisms of action, we hypothesize
that Noscapine in combination with Doxorubicin will produce
additive or synergistic cytotoxic effects in human TNBC in vitro
and in vivo possibly by inactivation of NF-KB and also via
antiangiogenic and apoptotic activity. The objectives of this study
are (a) to examine the anticancer activity of Noscapine alone and
combination with Doxorubicin against TNBC cells, and (b)
evaluate the antitumor effect of Noscapine alone and combination
in mice bearing MDA-MB-231 xenograft TNBC tumors and
elucidates underlying mechanism of action.
Materials and Methods
Noscapine and Doxorubicin were purchased from Sigma
Chemicals, St. Louis, MO, USA and Spectrum Chemicals USA.
The human breast cancer cell lines MDA-MB-231 and MDA-
MB-468 were obtained from American Type Culture Collection
(Rockville, MD, USA). Cells were grown in DMEM:F12K
medium (Sigma, St. Louis, MO, USA) supplemented with 10%
fetal bovine serum. The cell culture media contained antibiotic
antimycotic solution of penicillin (5,000 U/ml), streptomycin
(0.1 mg/ml), and neomycin (0.2 mg/ml). The cells were main-
tained at 37uC in the presence of 5% CO2 in air. The cells were
maintained at 37uC in the presence of 5% CO2. All other
chemicals were either reagent or tissue culture grade.
Animals
Female Nu/Nu mice (six weeks old form Harlan, Indianapolis,
IN) were grouped and housed (n=8 per cage) in sterile
microisolator caging unit supplied with autoclaved Tek-Fresh
bedding. The animals were kept under controlled conditions of
12:12 hour light: dark cycle, 2262uC and 50615 percent relative
humidity. The mice were fed (irradiated rodent chow Harlan
Teklad) and autoclaved water ad libitum. The animals were
housed at Florida A and M University in accordance with the
standards of the Guide for the Care and Use of Laboratory Animals and the
Association for Assessment and Accreditation of Laboratory
Animal Care.
In-vitro cytotoxicity studies
The MDA-MB-231 or MDA-MB-468 TNBC cell lines were
plated in 96-well micro titer plates, at a density of 1610
4 cells/well
and allowed to incubate overnight and were treated with various
dilutions of Noscapine made in cell growth medium (10 to
160 mM) from Noscapine stock solution in DMSO. The cells were
incubated for 72 h at 3760.2uC in a 5% CO2-jacketed incubator.
To study the interaction between Noscapine and Doxorubicin, the
MDA-MB-231 or MDA-MB-468 cells were treated with various
dilutions of Doxorubicin in the presence or absence of Noscapine
at 10, 20 and 30 mM. The plates were incubated for 72 h at
3760.2uC in a 5 percent CO2-jacketed incubator. Cell viability in
each treatment group was determined by crystal violet dye assay.
Separate study was done to find out the IC50 values of Noscapine
and Doxorubicin for the MDA-MB-231 and MDA-MB-468 cells.
Data analysis for the combination treatments
The percentage of cell survival as a function of drug
concentration was then plotted to determine the IC50 value (the
drug concentration needed to prevent cell proliferation by 50%)
[18,24]. The interactions between Doxorubicin and Noscapine
were evaluated by isobolographic analysis, a dose-oriented
geometric method of assessing drug interactions [25]. For 50
percent toxicity, the combination index (CI) values were calculated
based on the equation stated below.
CI~
D1
Dx1
z
D2
Dx2
za
D1   D2
Dx1   Dx2

ð1Þ
Where,
Dx1=Dose of drug 1 to produce 50 percent cell kill alone;
D1=Dose of drug 1 to produce 50 percent cell kill in
combination with D2;
Dx2=Dose of drug 2 to produce 50 percent cell kill alone;
D2=Dose of drug 2 to produce 50 percent cell kill in
combination with D1;
a=0 for mutually exclusive or 1 for mutually non-exclusive
modes of drug action.
Induction of apoptosis in MDA-MB-231 cells
To detect apoptotic cells, the ApoTag Red In Situ Apoptosis
detection kit
R (Chemicon
R International, CA, USA) was used.
MDA-MB-231 cells were plated at a density of 1610
6 cells/well in
6-well plates and incubated overnight. Cells were treated with
Doxorubicin (0.4 mg/ml), or Noscapine (30 mM), or combination.
Untreated cells were used as control. After 72 h, cells were fixed in
4% paraformaldehyde and mounted onto slides using Cytospin
R
(Shandon). Equilibration buffer was added to slides and incubated
for 10 minutes followed by incubation in working strength TdT
enzyme at 37uC for 1 hour. The slides were incubated in stop/
wash buffer for 10 minutes at room temperature. Working
strength anti-digoxinenin conjugate (rhodamine) was added to
each slide for 30-minute incubation at room temperature. The
images on the slides were visualized with an Olympus BX40
fluorescent microscope equipped with a computer-controlled
digital camera (DP71, Olympus Center Valley, PA, USA). To
quantify the apoptotic cells from terminal deoxynucleotidyl
transferase-mediated nick end labeling (TUNEL) assay, 100 cells
from 6 random microscopic fields were counted.
In-vivo antitumor effect against MDA-MB-231 tumors
The adherent MDA-MB-231 tumor cells were washed with
PBS, harvested from confluent cultures by 5-minute exposure to
0.25 percent trypsin and 0.02 percent EDTA solution in an
incubator. Trypsinization was stopped with medium containing 10
percent FBS. The cells were centrifuged at 500 g for 4 min at 4uC
and the floating cells in the supernatant were discarded. The cell
pellet was resuspended in medium containing 10 percent FBS and
mixed thoroughly. Trypan blue staining was used to determine the
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3610
6 cells/100 ml were prepared in cell growth medium. The
100 ml of cell suspension was injected subcutaneously into right
flank area of each mouse [18]. The protocol for in-vivo experiments
with nude mice was approved by the Animal Care and Use
Committee, Florida A and M University, Tallahassee, FL. The
mice were randomized into vehicle control and treatment groups
(n=8) when xenografts were palpable with a tumor size of
approximately 50 mm
3. The mice were treated with i) 160 mlo f
vehicle; ii) Noscapine (150 mg/kg/day); iii) Noscapine (300 mg/
kg/day); iv) Noscapine (450 mg/kg/day); v) Noscapine (550 mg/
kg/day); vi) Doxorubicin (1.5 mg/kg/week, i.v.), vii) Noscapine
(300 mg/kg/day)+Doxorubicin (1.5 mg/kg/week. i.v.). To check
for evidence of toxicity, the animals were weighed twice weekly.
The tumor dimensions were measured using a linear caliper and
tumor volume was calculated using following equation:
V mm3 ðÞ ~a  
b2
2

ð2Þ
Where,
V=tumor volume
a=largest diameter of tumor
b=smallest diameter of tumor
The mice were fed with food and water ad libitum. On day 38,
all animals were sacrificed by exposure to a lethal dose of
halothane in a desiccator. After dissection and removal of the
tumor tissues, the tumors were washed in sterile PBS. For
immunohistochemistry (IHC), and TUNEL assay procedures,
some of the tumors were fixed in formalin while others were
rapidly frozen in liquid nitrogen and stored in 280uC.
Western blotting analysis of xenograft MDA-MB-
231tumors
Tumor tissues harvested at 38 days post tumor implantation
from control, Noscapine, Doxorubicin and combination treated
mice were cut into small pieces and homogenized in PBS. The
homogenate was centrifuged at top speed for 10 min to sediment
the tissue fragments. The proteins were extracted using RIPA
buffer (50 mM Tris-HCL, pH 8.0, with 150 mM sodium chloride,
1.0 percent Igepal CA-630 (NP-40), 0.5 percent sodium deoxy-
chlolate, and 0.1 percent sodium dodecyl sulfate) with protease
inhibitor (500 mM phenylmethylsulfonyl fluoride). Samples were
vortexed, incubated on ice for 30 min, centrifuged again and the
supernatants were stored at 280uC. For WB, equal amounts of
supernatant protein (50 mg) from the control and different
treatments were denatured by boiling for 5 min in SDS sample
buffer (0.25 M Tris-HCl pH 6.8, 8% SDS, 30% Glycerol, 0.02%
Bromophenol Blue and 10% 2-beta-mercaptoethanol), separated
by 15% SDS-PAGE and transferred to nitrocellulose membranes
for immunoblotting. The membranes were blocked with 5 percent
skim milk in Tris-buffered saline with Tween 20 [10 mM Tris-
HCl (pH 7.6), 150 mM NaCl, 0.5 percent Tween 20] and probed
with NF-kb (1:500), IKBa (1:500), P-IKBa (1:500), Bax (1:1000),
Bcl2 (1:1000), caspase 3 (1:1000), cleaved caspase 3 (1:1000),
caspase 8 (1:1000), caspase 9 (1:1000), VEGF (1:500), survivin
(1:500) and b-actin antibodies (1:500). All primary antibodies were
purchased from Cell Signaling Technology (Beverly, MA). Bound
antibodies were revealed with HRP conjugated secondary
antibodies (1:2000) using SuperSignal West pico chemilumines-
cent solution (Pierce, Rockford, IL). Beta actin (Santa Cruz
Biotechnology) protein was used as a loading control. The
densitometric analysis of the bands was performed using the
program ImageJ v1.33u.
TUNEL assay of xenograft MDA-MB-231 tumors
Formalin-fixed tumor tissues harvested 38 days after tumor
implantation were embedded in paraffin and sectioned (4–5 mm
thick). DeadEnd
TM Colorimetric Apoptosis Detection System
(Promega, Madison, WI) was used to detect apoptosis in the tumor
sections placed on slides according to the manufacturer’s protocol.
Briefly, the equilibration buffer was added to slides and incubated
for 10 minutes followed by 10-minute incubation in 20 mg/ml
proteinase K solution. The sections were washed in PBS and
incubated with TdT enzyme at 37uC for 1 hour in a humidified
chamber for incorporation of biotinylated nucleotides at the 39-
OH ends of DNA. The slides were incubated in horseradish
peroxidase-labeled streptavidin to bind the biotinylated nucleo-
tides followed by detection with stable chromagen DAB. The
images on the slides were visualized with an Olympus BX40 light
microscope equipped with a computer-controlled digital camera
(DP71, Olympus Center Valley, PA, USA). Three slides per group
were stained and apoptotic cells were identified by dark brown
cytoplasmic staining.
Immunohistochemistry for Cleaved Caspase 3 and VEGF
Expression of MDA-MB-231 tumors
Tumor tissue sections prepared from formalin-fixed, paraffin-
embedded tumor tissues were used for IHC studies according to
the protocol specified in the SignalStain
TM Cleaved Caspase-3
(Asp 175) IHC kit (Cell Signaling, Beverly, MA). The section slides
were washed in xylene and hydrated in different concentrations of
alcohol. The slides were heated in sodium acetate solution at 95uC
for 10 minutes for antigen retrieval. The slides were washed three
times in PBS and incubated with the primary antibody against
cleaved caspase-3 overnight at 4uC. Horseradish peroxidase-
conjugated secondary antibody was applied to locate the primary
antibody. The specimens were stained with Nova Red stain and
counterstained with hematoxylin. The presence of brown staining
was considered a positive identification for activated caspase-3. For
VEGF staining, the tissue sections were washed, hydrated and
processed for antigen retrieval as described above for cleaved
caspase-3 staining. The samples were incubated overnight at 4uC
with either 1:50 dilution of VEGF antibody incubated with
biotinylated secondary antibody followed by streptavidin. The
color was developed by exposing the peroxidase to a substrate-
chromagen, which forms a brown reaction product. VEGF
expression was identified by the brown cytoplasmic staining.
The Olympus BX40 light microscope equipped with computer-
controlled digital camera (DP71, Olympus Center Valley, PA,
USA) was used to visualize the images on the slides.
CD31 expression and Assessment of Microvessel Density
of MDA-MB-231 tumors
Paraffin-embedded tumor tissues were deparaffinized and
blocked for peroxidase activity as described under methodology
for IHC for VEGF Expression. After washing with PBS, the
sections were pretreated in citrate buffer in a microwave oven for
20 min at 92–98uC. After two washes with PBS, specimens were
incubated in 10 percent normal goat serum (Atlanta Biologicals,
GA,USA) for 20 min to reduce the nonspecific antibody binding.
Subsequently, the sections were then incubated with a 1:500
diluted mouse CD31 monoclonal antibody (Cell Signaling Tech,
MA), which is recognized as an endothelial cell surface marker, at
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HRP Rabbit/Mouse (Santa Cruz Biotechnology, Santa Cruz,
CA,USA). After three washes with PBS, the section was developed
with diaminobenzidene-hydrogen peroxidase substrate, and lightly
counterstained with hematoxylin. To calculate microvessel density
(MVD), three most vascularised areas of the tumour (‘hot spots’)
were selected and mean values obtained by counting vessels. A
single microvessel was defined as a discrete cluster of cells positive
for CD31 staining, with no requirement for the presence of a
lumen. Microvessel counts were performed at6400 (640 objective
lens and 610 ocular lens; 0.74 mm
2 per field).
Statistics
One-way ANOVA followed by Tukey’s Multiple Comparison
Test was performed to determine the significance of differences
among groups using GraphPad PRISM version 3.0 software
(SanDiego, CA). Differences were considered significant in all
experiments at P,0.01 (*, significantly different from untreated
controls;
**, significantly different from Noscapine and Doxorubi-
cin single treatments.
Results
Cell proliferation inhibition by Noscapine and synergistic
behavior in combination with Doxorubicin
Noscapine inhibited proliferation of MDA-MB-231 and MDA-
MB-468 cells with an IC50 value of 36.1663.76 and 42.764.3 mM
respectively. Doxorubicin showed IC50 of 0.2160.09 mg/ml and
0.2060.08 mg/ml against MDA-MB-231 and MDA-MB-468
TNBC cells respectively. The combined effects of Doxorubicin
and Noscapine on cell proliferation were evaluated by isobolo-
graphic analysis method. The CI values ranged from 0.5160.03 to
0.6060.05 for 50 percent cell kill suggesting synergistic behavior
between Noscapine and Doxorubicin against both TNBC cells
(Table 1).
Induction of apoptotic DNA fragmentation in MDA-MB-
231 cells
Figure 1 shows that apoptosis is induced in MDA-MB-231 cells
following treatment with Doxorubicin, or Noscapine, or combi-
nation. Fig. 1A & 1B shows MDA-MB-231 cells undergoing
apoptosis following treatment with Noscapine 30 mM compared to
untreated cells. Combination treatment led to apoptosis in 7964
percent of treated MDA-MB-231 cells compared to 3263.0
percent and 2262.0 percent in Doxorubicin and Noscapine
respectively after 72 h (Fig. 1A and 1B). All treatments were
significantly different from control (* P,0.01). Doxorubicin or
Noscapine treatment was significantly different from combination
treatment (**, P,0.001).
Anti-tumor effect of Noscapine against MDA-MB-231
xenograft model
Figures 2A shows the tumor volume-time data profiles following
Noscapine administration at a dose of 150–550 mg/kg/day by
gastric lavage in mice xenografted with MDA-MB-231 tumors
compared to control. At 38 days post tumor implantation, the
tumor volumes were found to be 21026225 mm
3, 16486
172 mm
3, 1485.936146 mm
3, 11396103 mm
3 and 748683
mm
3 (expressed as mean6SEM) in control, Noscapine 150, 300,
450 and 550 mg/kg/day treated mice, respectively (Fig. 2A). Oral
administration of Noscapine at 150–550 mg/kg/day showed
significant (p,0.01) reduction in tumor volume in MDA-MB-
231 xenografts. However, Noscapine administered at 450 and
550 mg/kg/day showed very significant (p,0.001) reduction in
tumor volume. At the end of the study period (38 days), there were
21, 29, 45, and 64 percent reduction in the tumor volume
following Noscapine 150, 300, 450, 550 mg/kg/day treated mice
respectively compared to control. We found that Noscapine
treatment did not cause any apparent body weight loss in mice
(Fig. 2C).
Anti-tumor effect of Noscapine (300 mg/kg/day) and
Doxorubicin combination in MDA-MB-231 xenograft
model
The results (Fig. 2B) show that tumor volume significantly
decreased after treatment with Doxorubicin (1.5 mg/kg/week i.v.
bolus, P,0.01), Noscapine (300 mg/kg oral, P,0.01), or combi-
nation (P,0.001) compared to control. Tumor volume for the
combination treatment averaged 361664 mm
3 compared with
16486172 mm
3 for Noscapine treatment or 1259699 mm
3 for
Doxorubicin treatment on day 38 post tumor implantation. It is
evident that combination treatment was most effective in
inhibiting tumor growth compared to Doxorubicin or Noscapine
treatments. Furthermore, we did not observe any weight loss or
other signs of toxicity in the mice treated with combination or
Noscapine or Doxorubicin (Fig. 2D).
Inactivation of NF-KB, activation of proapoptotic and
inhibition of antiapopototic proteins in MDA-MB-231
xenograft model
Noscapine treatments significantly (P,0.001) decreased expres-
sion of NF-kB, IkBa, P-IkBa, BCl2 and increased expression of
cleaved PARP, Bax, activated caspase8, activated caspase 9,
Table 1. Combination Index (CI) values of the interaction between Nos with Dox against human MDA-MB-231 and MDA-MB-468
TNBC cells.
Drug Combinations MDA-MB-231 MDA-MB-468
CI at IC50 Interpretation Drug Combinations CI at IC50 Interpretation
Dox+Nos 10 0.5560.03 Synergism Dox+Nos 10 0.5160.03 Synergism
Dox+Nos 20 0.5960.04 Synergism Dox+Nos 20 0.5360.07 Synergism
Dox+Nos 30 0.6060.05 Synergism Dox+Nos 30 0.6060.04 Synergism
The human lung cancer cell lines MDA-MB-231 and MDA-MB-468 breast cancer cells were obtained from American Type Culture Collection (Rockville, MD). Different
concentrations of Nos were employed to study the effect on IC50 of Dox. Variable ratios of drug concentrations and mutually non-exclusive equations were used to
determine the CI. The CI values represent mean of four experiments. CI.1.3: antagonism; CI 1.1–1.3: moderate antagonism; CI 0.9–1.1: additive effect; CI 0.8–0.9: slight
synergism; CI 0.6–0.8: moderate synergism; CI 0.4–0.6: synergism; CI 0.2–0.4: strong synergism.
doi:10.1371/journal.pone.0017733.t001
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(Fig. 3) except Noscapine administered at 150 mg/kg/day
(P.0.05). The observed protein responses were found to be dose
dependant. The Bax/Bcl2 ratio of 0.62 was observed in control
tumors, while the Bax/Bcl2 ratio of 0.8, 1.1, 1.3, and 1.6 were
observed with Noscapine 150 mg/kg 300, 450, and 550 mg/kg
treated tumors respectively. A non-significant (P.0.05) increase in
Bax/Bcl2 ratio was observed with Noscapine 150 mg/kg/day,
while a significant (P,0.001) increase in Bax/Bcl2 ratio was found
with Noscapine 300, 450 and 550 mg/kg/day (Fig. 3A & 3B).
Results illustrated in Fig. 3A and 3B show that Noscapine,
Doxorubicin and combination treatment showed significant
(*, p,0.001) increased expression of Bax, activated caspase8,
activated caspase 9, caspase 3 and cleaved caspase 3 proteins and
decreased expression of NF-KB, IKBa, P-IkBa and Bcl2 compared
to control group. The expression of apoptotic and antiapoptotic
proteins in combination treatment was significantly (*, **, p,0.01)
different from single agent treatment groups.
Effects on angiogenic and cell survival proteins in
MDA-MB-231 xenograft model
We compared expression of angiogenic and survival protein in
tumor lysates from control and treated mice by western blotting
analysis using b-actin as loading control (Fig. 4). Noscapine
treatment significantly (P,0.001) decreased expression of VEGF
(Fig. 4A), and survivin (Fig. 4B) proteins except Noscapine at a
dose of 150 mg/kg (P.0.05) compared to control. Noscapine
treatment at 300, 450 and 550 mg/kg/day showed 0.14, 0.26 and
0.28 Fold decreased in VEGF expression inregressed tumor
compared to vehicle treated control group. Combination treat-
ment decreased expression of VEGF protein expression signifi-
cantly (**, P,0.001) to 0.45-fold compared to 0.14-fold with
Figure 1. Fluorescence Micrographs of cells stained with rhodamine and DAPI after 72 h (A) with Doxorubicin 0.4 mg/ml , Noscapine
30 mM, and, Noscapine and Doxorubicin combination in MDA-MB-231 cells and (B) Quantitation of apoptotic MDA-MB-231 cells
from TUNEL assay. DNA fragmentation indicated by positive staining (red) and nuclear condensation indicated by DAPI nuclear staining (blue).
Micron bar=100 mm. Cells were quantitated by counting 100 cells from 6 random microscopic fields. Data are expressed as mean+SD (N=6). One-
way ANOVA followed by post Tukey test was used for statistical analysis to compare control and treated groups. * P,0.01; all treatments significantly
different from control and ** P,0.01; significantly different from Noscapine and Doxorubicin single treatments.
doi:10.1371/journal.pone.0017733.g001
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treatment, respectively of controls in regressed tumors (Fig. 4A).
The expression of survivin protein were significantly decreased by
0.44 fold (*, P,0.01), 0.15 fold (*, P,0.05) and 0.08 fold
(*, P,0.05) with combination, Doxorubicin and Noscapine
treatment compared to control group respectively (Fig. 4B).
DNA fragmentation and expression of cleaved caspase-3
in MDA-MB-231 xenograft model
To further investigate the role of apoptosis, tumor sections
were stained with TUNEL for detection of DNA and expression
of cleaved caspase-3 (Fig. 5). Noscapine (150–550 mg/kg/day)
treated regressed tumors showed DNA fragmentation (Fig. 5A
and 5C) and widespread staining of activated cleaved caspase-3
expression compared to controls (Fig. 5B and 5D), indicating
that Noscapine induced apoptosis in a dose dependent fashion of
MDA-MB-231 breast cancer cells in-vivo. Single-agent treatment
with either Noscapine or Doxorubicin induced DNA fragmen-
tation (brown staining) that was further significantly (** P,0.001)
increased by combination treatment. The combination treatment
led to apoptosis in 6565 percent of the tumor cells, whereas
Noscapine and Doxorubicin induced apoptosis in percent 2063
and 3263 percent of the tumor cells respectively (Fig. 5A and
5C). Doxorubicin, Noscapine, and combination induced caspase-
3 expression in tumors which was significantly (P,0.01) different
compared to control tumors (Fig. 5 B and 5D). Combination,
Doxorubicin and Noscapine treatment showed 6864, 3362, and
2263 percent increased expression of cleaved caspase 3 in
tumors tissues respectively compared to control group (Fig. 5B
and 5D).
Inhibition of angiogenesis by combination in
MDA-MB-231 tumors
The highest expression of VEGF was seen in tumor tissues
harvested from untreated mice (Fig. 6A & 6C). Decreased VEGF
staining was observed in tumors treated with Noscapine (150–
550 mg/kg/day) in dose dependent manner and combination
(0.44-fold) compared to tumors treated with Doxorubicin (0.21-
fold) or Noscapine 300 mg/kg/day (0.1-fold) alone (Fig. 6A and
6C). CD31
+ endothelial cells were identified using IHC
technique in harvested tumor tissues and the results are shown
in Fig. 6B and 6D. The staining of CD31
+ in Noscapine treated
groups were significantly decreased to 0.05, 0.09, 0.18, and 0.28-
fold at doses of 150, 300, 450, and 550 mg/kg/day compared to
control group respectively. The staining of CD31
+ in combina-
tion, Doxorubicin (1.5 mg/kg) and Noscapine (300 mg/kg)
treated groups were significantly decreased to 0.40, 0.17, and
0.09-fold compared to control group. The average microvessel
per field in groups treated with Noscapine, Doxorubicin and
combination were found to decreased by 1062.6 (P,0.05),
17.663.5 (P,0.01), and 40.665.0 (P,0.001) respectively
compared control group.
Figure 2. Progression profile of tumor growth kinetics of in-vivo antitumor effect of different doses of Noscapine alone (A) and in
combination with Doxorubicin (B) on human MDA-MB-231 tumor xenograft model (tumor volumes, mm
3 ± SEM), and
measurement of body weight following Noscapine alone (C) and combination with Doxorubicin (D). Female nude mice with xenograft
MDA-MB-231 tumor tumors received various treatments for 38 days starting on day 7 post tumor implantation. The mice were treated with
Noscapine (150–550 mg/kg/day), Doxorubicin 1.5 mg/kg i.v. bolus, q3d67 schedule, and Noscapine 300 mg/kg/day+Doxorubicin 1.5 mg/kg i.v.
bolus, q3d67 schedule. Control group received vehicle only. Statistical significance of the difference in tumor volume of treatment groups compared
with control. P,0.01 (*, significantly different from untreated controls;
**, significantly different from Noscapine and Doxorubicin single treatments).
Data presented are means and SE (n=8). This experiment was repeated twice.
doi:10.1371/journal.pone.0017733.g002
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TNBC has a more aggressive clinical course than other forms of
breast cancer [1,4]. Traditionally, chemotherapy has been the
mainstay of systemic treatment for TNBC since currently available
endocrine and HER2-directed therapies are ineffective. [21]
Among anticancer agents, antimicrotubules (taxanes and vinca
alkaloids) constitute one of the most effective chemotherapeutic
agents for treatment of breast cancers. [7] However, their clinical
utility is limited due to the development of drug resistance and
associated severe side effects. [9,10] Noscapine is a safer orally
active antimicrotubule agent showed in-vitro and in-vivo antitu-
mor activity against variety of cancers including tumors resistant to
conventional antimicrotubular agents [13,14,15,16,17,18,19] and
did not exhibit severe side effects that are commonly seen with
many chemotherapeutic agents. [13,14] Doxorubicin is an
anthracycline drug which has shown significant anticancer activity
against TNBC; [22] however its clinical utility has been limited
due to low therapeutic index and associated adverse side effects
[23]. In the present study, we demonstrated that Noscapine in
combination with Doxorubicin was effective in a synergistic
manner in inhibition of tumor growth of TNBC both in vitro and
in vivo. Our results indicate that the anticancer activity of
Noscapine alone and in combination with Doxorubicin was
mediated via inactivation of NF-KB, induction of apoptosis, and
inhibition of angiogenesis.
To our knowledge, this is the first study that demonstrates
effectiveness of Noscapine in combination with Dox against
TNBC. In this study, we demonstrated that Noscapine inhibits
MDA-MB-231 and MDA-MB-468 cells proliferation in-vitro with
IC50 value of 36.1663.76 and 42.764.3 mM respectively which
was comparable with IC50 observed with MCF-7 breast
(IC50=42.3mM), HeLa (IC50=25mM), and thymocyte
(IC50=10mM) cells. [19] The antiproliferative activity of
Noscapine was found to vary with the type and sensitivity of
cancer cells. We used MDA-MB-231 and MDA-MB-468 TNBC
cells to ascertain interaction between Noscapine (sub IC50
concentration) and Doxorubicin using isobolographic method.
We selected the isobolographic analysis method since it has been
widely used to evaluate the interaction between two antitumor
drugs and provide both qualitative and quantitative measure of
nature and extent of drug interaction. [26] In the present
investigation, isobolographic analysis showed that Noscapine
enhanced the cytotoxicity of Doxorubicin (CI values,0.59) in
MDA-MB-231 and MDA-MB-468 cells in a synergistic manner
(Table 1). We recently reported that the CI values of ,1.0 are
indicative of synergistic interactions in A549 and H460 cells using
DIM-C-pPhC6H5 in combination with Docetaxel [25]. Similarly,
our recently conducted studies showed that the interaction
between Noscapine and Cisplatin was synergistic (CI,0.6)
against non–small cell lung cancer H460 and A549 cells [27].
Also, Hiser et al demonstrated that Noscapine in combination
Figure 4. Western blotting of tumor tissue lysates to determine expressions angiogenesis-related proteins expression of (A) VEGF
and (B) survivin proteins in tumors and quantitation of protein expression. Whole-cell lysates from control-untreated and treated tumors
were analyzed by western blotting for protein expressions. Lane 1=control; Lane 2=Noscapine 150 mg/kg/day ; Lane 3=Noscapine 300 mg/kg/day
; Lane 4=Noscapine 450 mg/kg/day; Lane 5=Noscapine 550 mg/kg/day; Lane 6=Doxorubicin 1.5 mg/kg i.v. bolus, q3d67 schedule; Lane
7=Combination (Noscapine 300 mg/kg/day+Doxorubicin ). Similar results were observed in replicate experiments. Protein expression levels (relative
to b-actin) were determined. Mean 6 SE for three replicate determinations. One-way ANOVA followed by post Tukey test was used for statistical
analysis. P,0.01 (*, significantly different from untreated controls;
**, significantly different from Noscapine and Doxorubicin single treatments).
doi:10.1371/journal.pone.0017733.g004
Figure 3. Western blotting of tumor tissue lysates to determine expressions apoptosis-related proteins (A) expression of NF-kb,
IKBa, P-IKBa, Bax, Bcl2, caspase 3, cleaved caspase 3, activated caspase 8 and activated caspase 9 proteins in tumor lysates by
western blotting and (B) quantitation of apoptotic protein expression. Tumor tissue lysates harvested tumor tissues from control-untreated
and treated groups were analyzed by western blotting for protein expressions. Lane 1=control; Lane 2=Noscapine 150 mg/kg/day; Lane
3=Noscapine 300 mg/kg/day; Lane 4=Noscapine 450 mg/kg/day; Lane 5=Noscapine 550 mg/kg/day; Lane 6=Doxorubicin 1.5 mg/kg i.v. bolus,
q3d67 schedule; Lane 7=Combination (Noscapine 300 mg/kg/day+Doxorubicin1.5 mg/kg i.v. bolus, q3d67 schedule). Similar results were observed
in triplicate experiments. Protein expression levels (relative to b-actin) were determined. Mean 6 SE for three replicate determinations. One-way
ANOVA followed by post Tukey test was used for statistical analysis. P,0.01 (*, significantly different from untreated controls;
**, significantly different
from Noscapine and Doxorubicin single treatments).
doi:10.1371/journal.pone.0017733.g003
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lymphoblastic CCRF-CEM and acute myelogenous leukemia
HL-60 cells. [28] Inhibition of cell proliferation and/or induction
of apoptotic cell death are key mechanisms by which chemo-
therapeutic agents exert their action [29]. To study the possible
mechanism involved in the anticancer activity of Noscapine and
combination, we evaluated induction of apoptosis of MDA-MB-
231 cells. The TUNEL assay results showed induction of
apoptosis at Noscapine 30 mM alone and in combination with
Doxorubicin at 0.4 mg/ml of compared to untreated cells which
was evident from positive TUNEL staining and chromatin
condensation (Fig. 1). Induction of apoptosis has been demon-
strated following Noscapine treatment in various types of human
cancer cells like ovarian [14], H460 lung, [18] Hela and mouse
thymocytes [19]. Combination treatment showed significant
(P,0.001) induction of apoptosis in a synergistic manner in
compared to single agent (Fig. 2). Similar to our results,
combination treatment of Noscapine (150 mg/kg by gavage once
daily) and
60Co radiation (single fraction - 25 Gy) showed
significant (P,0.01) decreased proliferation and increased
apoptosis (TUNEL positive cells) of GL261 tumor cells compared
to single agent treatment [30].
After establishing the efficacy of Noscapine alone and
combination with Doxorubicin on TNBC cells in-vitro, we
designed in-vivo experiments to test the efficacy of Noscapine in
combination with Doxorubicin against MDA-MB-231 xenograft
model in nude mice. Our previous studies have shown dose
dependant tumor reduction following oral administration of
Noscapine (300–550 mg/kg) against lung cancer [18]. Therefore,
we evaluated Noscapine in-vivo antitumor efficacy at different dose
levels ranging from 150 to 550 mg/kg/day against MDA-MB-231
xenograft model in mice administered by oral gavage. Our results
demonstrated that Noscapine at 550 mg/kg (p,0.01) through oral
gavage showed higher reduction in tumor volume in MDA-MB-
231 xenograft model compared to lower doses used (Fig. 3A).
Similarly, Aneja et al reported that oral Noscapine (300 mg/kg)
was able to suppress breast cancer progression in a xenograft
model (s.c. inoculated 10
6 MDA-MB-231 cells) by 66 percent
compared to control treatment at 24 days post tumor inoculation
[20]. We observed 29 percent reduction in the tumor volume
following Noscapine 300 mg/kg/day treatment compared to
control due to use of 3610
6 MDA-MB-231 cells for s.c.
inoculation and assessment of in vivo efficacy at 38 days post
tumor inoculation.
Previous reports have indicated that Noscapine (120 mg/kg/
day, intraperitoneally) was effective in regressing MCF-7 breast
tumors but the cell lines used were different than in our study. [19]
In another investigation, oral administration of Noscapine at a
dose of 300 mg/kg/day showed a significant regression of
melanoma tumors compared to untreated animals [13]. The dose
dependant antitumor activity of Noscapine in TNBC xenograft
model may be attributed to: a) short plasma half life and its
Figure 5. Immunohistochemical staining of xenograft MDA-MB-231 breast tumor tissues for induction of apoptosis using TUNEL
assay (A); for expression of cleaved caspase 3 (B); quantitation of apoptotic cells from TUNEL staining (C); and quantitation of
caspase 3 positive cells apoptotic cells (D). Tumor sections were stained using the DeadEnd colorimetric kit and cleaved caspase-3 (Asp 175)
IHC kit for TUNEL assay and cleaved caspase 3 expression as described in materials and methods respectively. The apoptotic tumor cells are stained
brown. Percentages of TUNEL-positive and cleaved caspase 3-positive cells were quantitated by counting 100 cells from 6 random microscopic fields.
Data are expressed as mean+SD (N=6). One-way ANOVA followed by post Tukey test was used for statistical analysis to compare control and treated
groups. P,0.01 (*, significantly different from untreated controls;
**, significantly different from Noscapine and Doxorubicin single treatments).
Original magnification 640 (Micron bar=100 mm).
doi:10.1371/journal.pone.0017733.g005
Noscapine Enhances Doxorubicin Activity
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17733availability at the tumor site; and b) extensive first-pass metabolism
that reduces the oral bioavailability of Noscapine [31,32]. There
are very few reports available in literature on oral Noscapine
absorption and pharmacokinetic parameters and a detailed
systematic study is desirable. Our future studies will focus on
improving the tumor targeting of Noscapine, so that it is effective
at lower doses.
We evaluated the in vivo antitumor efficacy of combination in
MDA-MB-231 xenograft tumors in Nu/nu mice using sub
therapeutic dose of Noscapine 300 mg/kg/day administered by
oral gavage and Doxorubicin 1.5 mg/kg/week by i.v. injection.
Our in vivo results demonstrate synergistic behavior of combina-
tion in murine MDA-MB-231 xenograft tumor model. Interest-
ingly, Noscapine, Doxorubicin and combination treatment
showed non-significant change in weight loss suggesting favorable
toxicity profile of Noscapine and Doxorubicin (Fig. 3C). Combi-
nation treatment will be advantageous over conventional taxane
based combination therapy in treatment of TNBC due to
improved patient compliance by oral administration of Nosca-
pine with minimal adverse side effects. Landen et al. showed
that in vivo anticancer activity of Noscapine at 300 mg/kg was
comparable to that of paclitaxel 25 mg/kg against murine B16LS9
xenograft melanoma model [13]. However, neither additive nor
synergistic effect was observed with Noscapine and Paclitaxel
combination. Studies in our laboratory also showed that
Noscapine and Docetaxel combination was neither additive nor
synergistic against NSCLC both in vitro and in vivo which
suggests that there was possibly a competition for the same target
(unpublished data). On the contrary, our recent investigation
demonstrated that Noscapine enhanced the anticancer activity of
Cisplatin in an additive to synergistic manner against H460 lung
xenografts model [27].
Several studies have provided evidence that enhanced tumor
growth inhibition of breast tumors can be achieved by combining
Doxorubicin with other agents such as zoledronic acid [33],
interleukin-2 [34], TGFb Inhibitor [35], tetrathiomolybdate [36]
as opposed to treating with single agent. In vivo studies by
Bandyopadhyay et al showed that the small TGFb Inhibitor,
TGFb1 (1 mg/kg every alternative day) and Doxorubicin (4 mg/
kg or 8 mg/kg once per 7 days) combination reduced tumor
growth and lung metastasis by inhibition of epithelial-mesenchy-
mal transition in the 4T1 orthotopic xenograft model in
comparison to single treatments [35] and these results are
consistent with those observed in our study.
To elucidate the underlying mechanism of action of Noscapine
and combination treatment, we have evaluated the expression of
NF-kB signaling, apoptotic, angiogenic and cell survival proteins
using western blot. NF-kB mediates survival signals that inhibit
apoptosis as well as promote cancer cell growth. [37] Recent
reports indicate that Noscapine exerts inhibitory effect on NF-KB
Figure 6. Immunohistochemical staining of MDA-MB-231 tumor tissues for (A) VEGF expression. Tumor sections were stained using the
ABC staining kit as described in Materials and Methods. Cells showing positive VEGF expression are stained brown. Original magnification 640.
(Micron bar=100 mm). Immunohistochemical staining of MDA-MB-231 tumor tissues for (B) CD31 expression. Tumor angiogenesis was assessed by
immunohistochemical staining with anti-CD31 antibody (brown) on paraffin-embedded sections. Original magnification640. (Micron bar=100 mm).
(C) Quantitation of apoptotic cells from VEGF staining. (D) Assessment of microvessel density. Microvessel density (MVD) was calculated by selecting
three most vascularised areas of the tumour (‘hot spots’) and mean values obtained by counting vessels. A single microvessel was defined as a
discrete cluster of cells positive for CD31 staining, with no requirement for the presence of a lumen. Microvessel counts were performed at 6400
(640 objective lens and610 ocular lens; 0.74 mm
2 per field). The MVD was significantly different between the control group and treated groups in
sequential analysis; **, P,0.01;* P,0.05 relative to control.
doi:10.1371/journal.pone.0017733.g006
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treatment inhibited NF-kB activation through inhibition of IKK
activation, IkBa phosphorylation, and IkBa degradation in MDA-
MB-231 xenograft TBNC tumors. Previous studies demonstrated
that Noscapine induces multiple proapoptotic responses that
induce apoptosis against variety of tumors [14,18,39,40,41,42].
Caspases are critical protease mediators of apoptosis triggered by
different stimuli. [43] In the present study, we found that the
Noscapine and combination treatment activated initiator caspases,
such as caspase-8 and caspase-9 followed by activation of effector
caspase-3. Results of our in vivo studies also demonstrate that
Noscapine alone and combination treatment induced proapototic
(Bax) or decreased Bcl2 proteins (Fig. 3A and 3B) suggesting
involvement of mitochondrial pathway. [39] Induction of
apoptosis and expression of cleaved caspase 3 was significantly
induced in vivo by combination treatment compared to Noscapine
or Doxorubicin alone thus confirming that apoptosis is an
important pathway associated with the anticancer activity of these
compounds (Fig. 5A–D). Our recently published studies with
Noscapine and Cisplatin combination also showed that their
anticancer activity was mediated by induction of apoptosis via
intrinsic and extrinsic pathways and inhibition of survival proteins
in H460 lung tumors [27]. Ye et al demonstrated increased
apoptotic activity in regressed tumor tissues following Noscapine
treatment at 120 mg/kg/day against MCF-7 breast and Renal
1983 bladder tumor xenografts [19]. Our previous studies also
showed induction of apoptosis and activation of cleaved caspase 3
following Noscapine treatment in the dose range of 300–550 mg/
kg/day in H460 xenografts [18]. Our in-vivo results showed
increased apoptotic activity and correlated very well with our
in-vitro results. Wang et al demonstrated that Zoledronic Acid and
Doxorubicin combination therapy led to significant (P,0.05)
increase in caspase-3–positive cells in MDA-G8 breast tumor
xenografts compared to single agent therapy. [33] To gain more
insights on the anticancer mechanisms of combination therapy,
other non-apoptotic signaling pathways need to be investigated
and these studies are in progress.
Angiogenesis is critical for establishing solid tumor growth and
metastasis [44]. In this investigation, we observed that Noscapine
and combination treatment significantly (p,0.001) decreased
expression of VEGF (Fig. 4D) in regressed tumors compared to
single agent treatment thereby suggesting inhibition of angiogen-
esis. In addition, Doxorubicin, Noscapine and combination
treatment decreased expression of cell survival protein survivin
which promotes angiogenesis in TNBC tumors (Fig. 4A and 4B).
Survivin was strongly upregulated in angiogenically stimulated
endothelium in vitro and in vivo which protects endothelial cells
from apoptosis. [44] The down regulation of survivin was
correlated with down regulation of VEGF by Noscapine and
combination treatment. Survivin also inhibits caspase activation
and acts as a negative regulator [45]. Therefore, the down-
regulation of survivin expression results in activation of caspases
and thereby induces apoptosis in tumor cells. Furthermore, our
IHC results show that Noscapine and combination treatment
decreased VEGF staining in tumor tissues harvested from mice
compared to single agent treatment and control (Fig. 6A and 6C).
The tumor regression by Noscapine and combination was also
mediated through decreased expression of VEGF and correlated
very well with our VEGF expression results obtained with
western blots of tumor lysates (Fig. 4D). MVD is a commonly
used index of tumor angiogenic activity and we counted density
of neovessels in histological sections of the tumor using CD31
staining. The CD31 expression (Fig. 6 B) and the average
microvessels per field (Fig. 6D) in combination treated group
were significantly (p,0.001) decreased compared to the single
agent treated and control group. The decreased expression of
angiogenic markers (IHC) and MVD in treatment compared to
control groups appeared to correlate with our western blot
results. Thus, Noscapine alone and in combination with
Doxorubicin exhibited antiangiogenic activity, and the underly-
ing mechanism is currently being further investigated in our
laboratories.
In conclusion, our data provides compelling evidence that
combination treatment is effective against MDA-MB-231 TNBC
cells as well as tumor xenografts by inactivation of NF-kB,
induction of apoptosis and inhibition of angiogenesis. While, the
currently available chemotherapeutic agents are associated
debilitating toxic side effects, oral Noscapine provides promise as
an effective anticancer agent with significantly lower toxicity on
normal cells. Thus the use of synergistically acting Noscapine and
Doxorubicin combination therapy could be an innovative and
promising therapeutic strategy for the treatment for TNBC and
possibly will have fewer adverse side effects compared to currently
available chemotherapeutic regimens.
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